Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.61% | 1.00% | -1.88% | 0.90% | 30.99% |
| Total Depreciation and Amortization | 8.12% | 7.63% | 9.49% | 7.67% | 5.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -63.10% | -77.80% | 101.01% | -24.54% | -54.37% |
| Change in Net Operating Assets | 79.67% | 32.09% | 80.78% | 91.38% | -258.32% |
| Cash from Operations | 42.28% | 6.99% | 14.31% | 11.18% | -86.14% |
| Capital Expenditure | 28.57% | -480.00% | -350.00% | -- | -40.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 28.57% | -1,480.00% | -350.00% | -- | -40.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.36% | -42.11% | -2,144.44% | 78.49% | -7,147.83% |
| Issuance of Common Stock | -46.67% | -96.42% | 63.11% | -99.95% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 43.19% | 75.90% | 119.32% | -105.28% | -83.54% |
| Cash from Financing | -36.37% | -97.41% | 56.80% | -109.02% | 169.10% |
| Foreign Exchange rate Adjustments | -- | -50.00% | 100.00% | 146.15% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.29% | -162.06% | 391.52% | -1,658.96% | 220.35% |